ClinicalTrials.gov
public full text
Public Domain
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with breast cancer that can be removed by surgery.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer#877547
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer#837240
- Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery#1282822
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer#1163770
- Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer#859504
Record · ID 1244686
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive